ASCO 2019 Poster Presentation Shows Improved Overall Survival for Advanced Pancreatic Cancer Patients Enrolled in the Know Your Tumor Program

Initial results from the KYT program demonstrated that 27% of pancreatic cancer patients harbor highly actionable molecular alterations, defined as biomarkers that predict for a high response rate to appropriately targeted therapies.